[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"graves-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:graves-disease":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,51,75,106,138,160,178,204,226,241,267,293,317,344,378,402,422,448,474,495,516,541,564,585,609],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100616454","phase-1-nexus-study-a-study-to-test-single-and-multiple-doses-of-mer511-given-to-adults-with-graves-disease-100616454",false,"NCT07305818","NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease","A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease","Inclusion Criteria:\n\n1. Adults 18 to 65 years of age, inclusive, at the time of signing the ICF\n2. Documented GD diagnosis,\n3. Receiving stable dose of ATD (Antithyroid drug)\n4. Body weight at least 50 kg (110 lb) and body mass index (BMI) 18.0-35.0 kg\u002Fm2, inclusive\n5. Women of childbearing potential must agree to use highly effective contraceptive methods\n6. Men with partners of childbearing potential or who are pregnant must agree to use a condom or strict abstinence\n7. Signed informed consent to participate in the study\n8. Willingness and ability, in the opinion of the investigator, to comply with protocol requirements and restrictions (eg, dosing, schedule of assessments).\n\nExclusion Criteria:\n\n1. History of:\n\n   1. total thyroidectomy.\n   2. History of hyperthyroidism not caused by GD (eg, toxic adenoma, toxic multinodular goiter).\n   3. History of thyroid storm.\n   4. History of agranulocytosis, anemia, leukopenia, thrombocytopenia, vasculitis, or liver toxicity due to prior ATD therapy Treatment with RAI therapy within 12 months prior to Screening\n2. Likely to require definitive treatment for GD (RAI therapy or thyroidectomy) during the study, based on GD history and anticipated prognosis.\n3. Use of levothyroxine, desiccated thyroid extract, or T3 at any dose within 6 weeks prior to Screening.\n4. Current active or chronic moderate-to-severe TED per EUropean Group On Graves' Orbitopathy (EUGOGO) criteria as judged by the investigator at Screening\n5. History of TED-directed medical treatment (including IV\u002Foral steroids, immunosuppressants, or teprotumumab), surgical treatment, and\u002For orbital radiation within 3 months prior to Screening, or per required prohibited concomitant therapy washout criteria in the protocol (whichever is longer)\n6. Major surgery or use of iodinated contrast within 3 months prior to planned IMP dosing.\n7. Active systemic autoimmune disease requiring treatment that causes undue risk in the opinion of the investigator.\n8. History of cardiovascular, respiratory, renal, gastrointestinal, endocrinological (other than GD), hematological, immunodeficiency, or neurological disorders that may constitute a risk when taking the IMP or interfere with data interpretation.\n9. History of liver disease\n10. Pregnant, breastfeeding, or planning to become pregnant during the study\n11. Treatment with prohibited medications prior to planned IMP dosing or likely to require prohibited concomitant therapy during the study\n12. Live vaccine(s) or mRNA vaccine(s) within 1 month prior to IMP dosing, or plans to receive such vaccines during the study\n13. Treatment with any investigational drug within within 3 months or 5 half-lives (whichever is longer) prior to enrollment\n14. Total IgG level \\\u003C700 mg\u002FdL at Screening\n15. Any of the following at Screening (confirmed by single repeat measurement, if deemed necessary):\n\n    * ALT or AST \\>1.5 × ULN\n    * Total bilirubin \\>1.5 × ULN\n16. Estimated glomerular filtration rate (eGFR) \\\u003C75 mL\u002Fmin\u002F1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation\n17. Positive result for HIV antibody, HBsAg, or hepatitis C antibody with detectable viral RNA levels at Screening\n18. Positive drug screen or positive test for alcohol\n19. 12-lead ECG demonstrating any of the following at Screening:\n\n    * QTcF interval \\>450 ms\n    * QRS interval \\>120 ms\n    * PR interval \\>220 ms\n20. Blood pressure measurements demonstrating any of the following at Screening:\n\n    * Systolic blood pressure ≥140 mmHg\n    * Diastolic blood pressure ≥90 mmHg\n21. Heart rate \\\u003C45 bpm or \\>100 bpm\n22. Donated more than 500 mL of blood in the 2 months prior to signing the ICF\n23. Current enrollment or past participation within 3 months or 5 half-lives (whichever is longer) prior to signing the ICF in any other clinical trial involving an IMP\n24. Refusal to adhere to lifestyle considerations as defined in the protocol\n25. Employee of the investigator, clinic, or sponsor with direct involvement in the proposed study or other studies under the direction of the investigator or clinic, as well as family members of the employee or investigator\n26. Any other conditions that, in the opinion of the investigator or the sponsor, could interfere with participation in or completion of the study","ALL","18 Years","55 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.",[28],"Graves Disease",[30,31,32,33,34,35,36,37],"Graves' Disease","Hyperthyroidism","Basedow disease","Exophthalmic goitre","TSHR","Autoimmune","Anti-thyroid drugs","Autoimmune thyroid disease","RECRUITING","2026-06-30",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":42},"2025-12-19",{"date":46,"type":22},"2028-07-24",{"name":48,"class":49},"Merida Biosciences","INDUSTRY",9,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100641998","phase-3-study-to-determine-if-bhv-1300-is-effective-and-safe-in-adults-with-graves-disease-100641998","NCT07661056","Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease","A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease","Key Inclusion Criteria:\n\n1. Participants must have serologically confirmed Graves' disease as documented by presence of elevated autoantibodies\n2. Participants must have active hyperthyroidism due to Graves' disease\n\nKey Exclusion Criteria:\n\n1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter)\n2. History of treatment with radioactive iodine or thyroid surgery.\n3. Have received levothyroxine, desiccated thyroid extract, or T3 at any dose within six weeks of the Baseline\u002FDay 1 Visit.\n4. Thyroid storm, i.e. severe thyrotoxicosis with evidence of systemic decompensation (e.g., Burch-Wartkofsky Point Scale of ≥ 45 or Japanese Thyroid Association category 1 or 2, with accompanying manifestations including hyperpyrexia, tachycardia, arrhythmias, congestive heart failure, agitation, delirium, psychosis, stupor, and coma, as well as nausea, vomiting, diarrhea, or hepatic failure) within 6 weeks of Screening.\n5. Have autoimmune disease other than Graves' disease requiring treatment\n6. Have moderate to severe thyroid eye disease (TED) and are expected to require immediate surgical intervention and\u002For are planning corrective surgery\u002Firradiation or medical therapy for TED during study participation.\n7. Are expected to require urgent or emergent thyroid surgery or ablation within six weeks of Baseline\u002FDay 1 or throughout the study.","70 Years",{"count":60,"type":22},300,[62],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid",[28],[31],"2026-06-29",{"date":39,"type":42},{"date":69,"type":42},"2026-06-26",{"date":71,"type":22},"2028-02",{"name":73,"class":49},"Biohaven Therapeutics Ltd.",5,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100594352","phase-2-a-study-to-assess-the-efficacy-safety-and-tolerability-of-imvt-1402-as-treatment-for-adult-participants-with-graves-disease-100594352","NCT07018323","A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease","A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease","Inclusion Criteria:\n\n* Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures.\n* Male or female participants aged ≥ 18 years.\n* Participants with diagnosis of GD who are hyperthyroid despite ATD treatment.\n* Other, more specific inclusion criteria are defined in the protocol.\n\nExclusion Criteria:\n\n* Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy.\n* Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk.\n* Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and\u002For are planning corrective surgery\u002Firradiation or medical therapy for TED during study participation.\n* Additional exclusion criteria are defined in the protocol.","75 Years",{"count":84,"type":22},210,[86],"PHASE2","This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.",[30],[90,91,92,93,94,95],"IMVT-1402","Graves' disease","Thyroid-Stimulating Hormone Receptor","Immunoglobulin G","Antithyroid drug","Imeroprubart","2026-06-19",{"date":98,"type":42},"2026-06-23",{"date":100,"type":42},"2025-06-19",{"date":102,"type":22},"2027-05",{"name":104,"class":49},"Immunovant Sciences GmbH",149,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":116,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100594320","evaluating-an-ai-tool-for-detecting-thyrotoxic-states-100594320","NCT07017907","Evaluating an AI Tool for Detecting Thyrotoxic States","Performance Evaluation of the Software Medical Device to Detect the Thyrotoxic State in Patients With Hyperthyroidism","Inclusion Criteria:\n\n* Adults aged 22 years or older, regardless of sex.\n* Individuals who are newly diagnosed with Graves' disease or currently undergoing treatment for it.\n* Individuals who have received sufficient explanation about the investigational software and are able to use it appropriately.\n* Individuals who voluntarily agree to participate in the study and have signed informed consent, either directly or via a legally authorized representative.\n\nExclusion Criteria:\n\n* Individuals with cardiac conditions such as arrhythmia or heart failure.\n* Individuals taking medications that significantly affect heart rate, including antiarrhythmics or antihistamines. (Intermittent short-acting beta-blockers are allowed.)\n* Pregnant or breastfeeding individuals, or those planning pregnancy during the study period or not using appropriate contraception.\n* Individuals with significant comorbidities that interfere with follow-up or study compliance.\n* Individuals with severe psychiatric disorders, substance use disorder, or alcohol dependence.\n* Individuals deemed ineligible at the discretion of the investigator for safety or ethical concerns.","22 Years",{"count":115,"type":22},15,"12 Weeks","OBSERVATIONAL","This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism. The device utilizes heart rate data collected from commercially available wearable devices and compares it with thyroid function test results. The study will enroll patients diagnosed with Graves' disease, monitoring their heart rate during sleep and correlating these measurements with free T4 levels obtained through serial blood testing. No investigational device output will be disclosed to participants, and the study will not alter standard clinical care.",[28,120],"Hyperthyroidism\u002FThyrotoxicosis",[122,31,123,124,125,126,127],"Graves disease","Thyrotoxicosis","Artificial intelligence","Heart rate","SaMD","wearable device","2026-05-28",{"date":130,"type":42},"2026-06-01",{"date":132,"type":42},"2026-01-09",{"date":134,"type":22},"2026-12-31",{"name":136,"class":49},"THYROSCOPE INC.",1,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100591761","phase-2-a-study-to-investigate-the-efficacy-and-safety-of-rilzabrutinib-in-adult-participants-with-graves-disease-100591761","NCT06984627","A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","Inclusion Criteria:\n\n* Participants who have a confirmed diagnosis of Graves' disease with active hyperthyroidism, with or without active Graves' orbitopathy at the time of screening.\n* A subset of participants will have a diagnosis of active Graves' orbitopathy, as confirmed by ophthalmic exam at screening and a clinical activity score (CAS) ≥3 for the most severely affected eye, and associated with one or more of the following: lid retraction ≥2 mm, moderate or severe soft tissue involvement, proptosis ≥2 mm, and\u002For intermittent or constant diplopia.\n* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\n* History of hyperthyroidism not caused by Graves' disease (eg, hyperthyroidism due to toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis).\n* History of thyroid storm or at high risk of developing thyroid storm as determined by evaluating clinician.\n* Enlarged thyroid goiter causing upper airway obstruction and\u002For requiring surgical intervention during the study period.\n* For participant with Graves' orbitopathy, requires immediate surgical ophthalmological intervention or is planning corrective surgery\u002Firradiation during the course of the study.\n* Sight threatening Graves' orbitopathy or decreased visual acuity due to optic neuropathy within the last 6 months.\n* Corneal decompensation unresponsive to medical management.\n* Onset of Graves' orbitopathy symptoms \\>9 months prior to baseline.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",{"count":146,"type":22},30,[86],"This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.\n\nStudy details include:\n\n* Screening period (up to 4 weeks).\n* Treatment period (up to 16 weeks).\n* Follow-up period (4 weeks). The number of visits will be up to 13.",[30],"2026-05-21",{"date":152,"type":42},"2026-05-22",{"date":154,"type":42},"2025-09-02",{"date":156,"type":22},"2026-09-23",{"name":158,"class":49},"Sanofi",13,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},"100572003","phase-2-a-study-to-assess-the-efficacy-safety-and-tolerability-of-imvt-1402-as-treatment-for-adult-participants-with-graves-disease-100572003","NCT06727604",{"count":165,"type":22},240,[86],"This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.\n\nThe primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \\[T3\\] or free triiodothyronine \\[FT3\\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.",[30],[90,170,31,37,95],"Anti Thyroid Drug",{"date":152,"type":42},{"date":173,"type":42},"2024-12-17",{"date":175,"type":22},"2028-06",{"name":104,"class":49},134,{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},"100591455","phase-1-study-of-bhv-1300-in-graves-disease-100591455","NCT06980649","Study of BHV-1300 in Graves' Disease","An Open-Label Biomarker Study of BHV-1300 in Graves' Disease","Key Inclusion Criteria:\n\n1\\. Participants must have serologically confirmed Graves' Disease.\n\nKey Exclusion Criteria:\n\n1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and\u002For history of thyroid storm within six weeks of the Baseline visit.\n2. History of treatment with radioactive iodine or thyroid surgery.","65 Years",{"count":115,"type":22},[25],"The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.",[28],[37,191,192,193,194,195],"hyperthyroidism","anti thyroid drug","thyroid disease","autoimmune diseases","endocrine system diseases","2026-05-19",{"date":152,"type":42},{"date":199,"type":42},"2025-08-21",{"date":201,"type":22},"2027-09",{"name":73,"class":49},17,{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100640696","phase-3-a-study-to-assess-efficacy-and-safety-of-efgartigimod-ph20-sc-pfs-in-adult-participants-with-graves-disease-100640696","NCT07596849","A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.","A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs","VitaliThy","Inclusion Criteria:\n\n* Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.\n* Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \\>=ULN (upper limit of normal) at screening\n* Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \\\u003C0.1 mIU\u002FL at screening\n* Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening\n\nExclusion Criteria:\n\n* History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter)\n* History of RAI (radioactive iodine) therapy or received a total thyroidectomy\n* T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \\\u003C6 weeks before screening\n* Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.\n* Graves' orbitopathy\u002FThyroid Eye Disease (GO\u002FTED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and\u002For planned corrective surgery\u002Firradiation or medical therapy during the study",{"count":213,"type":22},230,[62],"The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.\n\nThe study consists of a part A double-blinded treatment period, a part B treatment\u002Fobservation period and a part C open-label treatment\u002Fobservation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.\n\nThe total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.",[28],"NOT_YET_RECRUITING","2026-05-13",{"date":196,"type":42},{"date":221,"type":22},"2026-06",{"date":223,"type":22},"2030-05",{"name":225,"class":49},"argenx",{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":209,"acronym":210,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":215,"conditions":234,"keywords":4,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":240,"locationsCount":4},"100636794","phase-3-a-study-to-assess-efficacy-and-safety-of-efgartigimod-ph20-sc-pfs-in-adult-participants-with-graves-disease-100636794","NCT07570316","A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease","Inclusion Criteria:\n\n* Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.\n* Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \\>=ULN (upper limit of normal) at screening.\n* Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \\\u003C0.1 mIU\u002FL at screening.\n* Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening.\n\nExclusion Criteria:\n\n* History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter).\n* History of RAI (radioactive iodine) therapy or received a total thyroidectomy.\n* T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \\\u003C6 weeks before screening.\n* Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.\n* Graves' orbitopathy\u002FThyroid Eye Disease (GO\u002FTED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and\u002For planned corrective surgery\u002Firradiation or medical therapy during the study.",{"count":213,"type":22},[62],[30,28],"2026-04-30",{"date":237,"type":42},"2026-05-06",{"date":221,"type":22},{"date":223,"type":22},{"name":225,"class":49},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":137},"100618596","early-phase-1-in-vivo-car-t-for-refractory-graves-disease-100618596","NCT07333677","In Vivo CAR-T for Refractory Graves' Disease","A Safety and Efficacy Study of in Vivo CAR-T (HN2301) for Refractory Graves' Disease","Inclusion Criteria (Participants must meet all of the following criteria to be eligible for this study):\n\n* Age 18-75 years (inclusive), male or female.\n* Refractory Graves' disease, defined as meeting at least one of the following: a) Continuous antithyroid drug (ATD) therapy for ≥3 years without achieving criteria for ATD discontinuation; b) Meeting criteria for ATD discontinuation but experiencing ≥2 relapses after ATD withdrawal.\n* Positive serum TRAb.\n* Willing to use effective contraception for 12 months after study drug administration.\n* Voluntarily agrees to participate in the study, has signed the informed consent form, and is able to comply with study procedures and follow-up requirements.\n\nExclusion Criteria (Participants meeting any of the following criteria will be excluded from the study):\n\n* History of severe drug allergy or known allergic predisposition.\n* Presence or suspected presence of uncontrolled active infection.\n* History of major organ transplantation (e.g., heart, lung, liver, kidney) or bone marrow\u002Fhematopoietic stem cell transplantation.\n* Presence of significant heart disease, such as angina, myocardial infarction, heart failure, or clinically significant arrhythmias.\n* Receipt of any mRNA-LNP product or other lipid nanoparticle (LNP)-based therapy within the past 2 years.\n* Receipt of a live vaccine within 30 days prior to screening.\n* History of malignant tumors.\n* Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA above the detection limit; positive hepatitis C virus (HCV) antibody with detectable HCV RNA; positive human immunodeficiency virus (HIV) antibody; or positive syphilis test.\n* Presence of psychiatric disorders or severe cognitive impairment.\n* Hematologic dysfuction at screening, defined as any of the following: a. Neutrophil count \\\u003C 1.8 × 10⁹\u002FL, b. Hemoglobin \\\u003C 110 g\u002FL, c. Platelet count \\\u003C 50 × 10⁹\u002FL\n* Impaired liver function, defined as any of the following: Alanine aminotransferase (ALT) \\> 3 × ULN, Aspartate aminotransferase (AST) \\> 3 × ULN, Total bilirubin \\> 2.5 × ULN.\n* Impaired renal function: creatinine clearance rate (CrCl) \\\u003C 60 mL\u002Fmin (Cockcroft-Gault formula).\n* Left ventricular ejection fraction (LVEF) \\\u003C 55%.\n* Coagulation abnormalities, defined as either: International normalized ratio (INR) \\> 1.5 × ULN, Prothrombin time (PT) \\> 1.5 × ULN\n* Pregnant or breastfeeding women.\n* Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.",{"count":74,"type":22},[250],"EARLY_PHASE1","Graves' disease is an autoimmune thyroid disorder characterized by the production of autoantibodies against the thyroid-stimulating hormone receptor (TRAb), leading to excessive thyroid hormone secretion and systemic manifestations. A subset of patients develop refractory disease, failing to achieve durable remission despite prolonged antithyroid therapy.\n\nThis study aims to evaluate the safety and efficacy of HN2301, an in vivo CAR-T therapy in which host T lymphocytes are engineered and transformed to functional CAR-T cells via CD8 antibody-coated LNP delivery of CD19 CAR-mRNA. Participants with refractory Graves' disease will receive three to five administrations of HN2301 and will be regularly monitored for changes in thyroid function, TRAb levels, clinical response, and treatment-related adverse events. The study will provide preliminary evidence on whether HN2301 can induce sustained remission of refractory Graves' disease.",[30],[254,255,256],"refractory Graves' disease","TSH receptor antibody","in vivo CAR-T","2026-03-18",{"date":259,"type":42},"2026-03-19",{"date":261,"type":42},"2026-01-29",{"date":263,"type":22},"2027-12",{"name":265,"class":266},"Shanghai Zhongshan Hospital","OTHER",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":274,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":137},"100629903","systemic-inflammation-thyroid-autoimmunity-and-neuroretinal-changes-in-graves-disease-100629903","NCT07480720","Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease","Relationship Between Systemic Inflammation, Thyroid Autoimmunity, and Neuroretinal Structures in Graves Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n\nDiagnosis of Graves' disease (for the patient group)\n\nNo known thyroid disease in healthy control participants\n\nAvailability of optical coherence tomography (OCT) measurements and laboratory data\n\nTime interval between OCT examination and blood sampling ≤ 10 days\n\nExclusion Criteria:\n\n* Presence of glaucoma, optic neuropathy, or retinal vascular diseases\n\nMacular diseases, uveitis, or severe refractive error (high myopia \\>6 diopters)\n\nDiabetic retinopathy\n\nHistory of previous intraocular surgery\n\nHistory of active infection, malignancy, or systemic inflammatory disease\n\nPoor-quality OCT measurements (segmentation errors or low signal strength)",true,{"count":21,"type":22},"This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.",[28,278],"Graves Ophthalmopathy",[122,280,281,282,283,284],"Thyroid autoimmunity","Systemic inflammation","Optical coherence tomography","Retinal nerve fiber layer","Graves ophthalmopathy","2026-03-14",{"date":257,"type":42},{"date":288,"type":42},"2026-03-01",{"date":290,"type":22},"2026-05-01",{"name":292,"class":266},"Elazıg Fethi Sekin Sehir Hastanesi",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":23,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":137},"100614981","phase-1-a-study-of-genssci098-in-subjects-with-graves-disease-100614981","NCT07286656","A Study of GensSci098 in Subjects With Graves' Disease","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Voluntary signed informed consent.\n* Confirmed diagnosis of diffuse toxic goiter (Graves' disease).\n* Abnormal thyroid function tests (e.g., elevated T4, and suppressed TSH).\n* No prior or recent use of antithyroid medications (discontinued for at least 4 weeks).\n* Female participants must be postmenopausal, surgically sterile, or using a highly effective method of contraception.\n* Male participants must agree to practice abstinence, use a highly effective method of contraception， or have undergone vasectomy.\n* Ability to comply with the follow-up schedule and understand and adhere to the study requirements.\n\nExclusion Criteria:\n\n* Non-diffuse toxic goiter-induced hyperthyroidism.\n* Previous radioactive iodine treatment or thyroid surgery.\n* History or risk of thyroid storm.\n* Use of thyroid hormone medications within the past 6 weeks.\n* accompanied by active thyroid eye disease.\n* Thyroid eye disease treated with radiation\u002Fsurgery,or need for urgent surgery surgical or medical intervention.\n* Optic nerve lesions or corneal damage.\n* Use of steroids or immunosuppressants within the past 3 months,or those who have used biologics within 6 months\n* Inability to quit smoking during the study.\n* Allergy to the study drug or monoclonal antibodies.\n* Participation in another clinical trial within the past 3 months.\n* Abnormal electrocardiogram.\n* Significant hepatic or renal dysfunction.\n* Pregnancy,breastfeeding,or positive pregnancy test.\n* Positive for HIV,syphilis,hepatitis B,or hepatitis C.\n* History of drug or substance abuse.\n* Other autoimmune diseases requiring treatment.\n* History of malignant tumors.\n* Splenectomy or major surgery within the past 6 months.\n* Severe cardiovascular,pulmonary,hepatic,renal,neurological,or hematological diseases.\n* Other conditions deemed unsuitable by investigators.",{"count":301,"type":22},24,[25],"To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease",[305,306,307,28],"Safety","Tolerability","GenSci098","2026-02-13",{"date":310,"type":42},"2026-02-17",{"date":312,"type":42},"2025-11-21",{"date":314,"type":22},"2027-03-18",{"name":316,"class":49},"Changchun GeneScience Pharmaceutical Co., Ltd.",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":325,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":137},"100624515","impact-of-thyroid-hormones-on-human-glucose-and-energy-metabolism-100624515","NCT07410637","Impact of Thyroid Hormones on Human Glucose and Energy Metabolism","Inclusion Criteria:\n\n* patients with initial diagnosis of graves disease OR\n* patients with initial diagnosis of thyroid carcinoma\n\nExclusion Criteria:\n\n* contraindications for oral glucose tolerance test\n* Diabetes mellitus\n* Fasting glucose level ≥ 200 mg\u002FdL\n* Exogenous insulin administration with action at the time of the test\n* Current disease with activation of stress hormones\n* Post-aggressive metabolism\n* Acute infectious disease",{"count":324,"type":22},60,[326],"NA","The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism.\n\nPatients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.",[28,329],"Thyroid Cancer",[331,332,333,334,335,191],"thyroid hormones","glucose metabolism","lipid metabolism","graves disease","thyroid cancer","2026-02-12",{"date":308,"type":42},{"date":339,"type":42},"2026-02-04",{"date":341,"type":22},"2031-06",{"name":343,"class":266},"University of Ulm",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":185,"enrollmentInfo":351,"targetDuration":4,"studyType":23,"phases":353,"briefSummary":354,"conditions":355,"keywords":362,"overallStatus":217,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":376,"locationsCount":4},"100624764","telehealth-music-therapy-for-adults-with-endocrine-disorder-and-depression-100624764","NCT07413874","Telehealth Music Therapy for Adults With Endocrine Disorder and Depression","Telehealth Music Therapy for Adults With Endocrine System Based Autoimmune Disease and a Depressive Disorder: An Intervention Development Study","Inclusion Criteria:\n\n* self-reported depression\n* self-reported autoimmune endocrine disease\n* 18-65 years of age\n* have a device that supports the Zoom platform (camera and audio)\n\nExclusion Criteria:\n\n* intellectual or developmental disability\n* no auto-immune disease\n* no depression\n* lack of access to device\n* under the age of 18 years\n* over the age of 65 years",{"count":352,"type":22},10,[326],"The goal of this clinical trial is to explore if a telehealth music therapy intervention helps with quality of life, depression symptoms, anxiety symptoms. It will also explore the participants' relationship to music. The main questions it aims to answer are:\n\n* Refine and tailor the music therapy intervention to fit the specific needs of adults living with an autoimmune disease and depression.\n* Examine the feasibility of the study protocol to support a future full-scale trial\n* Examine how music therapy impacts quality of life, depression symptoms, and anxiety symptoms\n* Explore how music therapy impacts one's relationship to music\n\nParticipants will:\n\n* have a short interview where you'll fill out a questionnaire with some basic information, answers about your depression, quality of life, and potential anxiety, and a question about how you feel about music at the start and end of the sessions\n* attend 8 weekly sessions, approximately 30-45 minutes each, with a board certified music therapist over telehealth\u002FZoom\n* answer a few questions about the music therapy intervention",[356,357,28,358,359,360,361],"Type 1 Diabetes","Hashimoto Disease","Addison Disease","Autoimmune Polyglandular Syndrome Type III","Depression","Endocrine System Diseases",[363,364,365,366,367,368,369,370],"type 1 diabetes","music therapy","behavioral health","psychosocial","diabetes","behavioral intervention","quality of life","telehealth","2026-02-10",{"date":310,"type":42},{"date":374,"type":22},"2026-02-01",{"date":134,"type":22},{"name":377,"class":266},"Appalachian State University",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":385,"maxAge":386,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":137},"100621318","phase-2-impact-of-vitamin-d-therapy-on-thyroid-function-and-antibody-levels-in-pediatric-graves-disease-100621318","NCT07369063","Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease","Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility Trial","Inclusion Criteria:\n\n* All new pediatric participants aged 9-17 years with a new diagnosis of GD who will be started on methimazole, will be offered to participate at the time of diagnosis.\n* Biochemical features include:\n* Suppressed TSH \\\u003C0.1.\n* Elevated T3\n* Elevated Free T4\n* Elevated T4\n* Positive TSI or TRAb. The presence of antibodies is diagnostic.\n* Our study will offer enrollment to non-English speaking participants\n\nExclusion Criteria:\n\n* Initial hydroxy vitamin D levels \\>80 ng\u002FmL\n* Hypocalcemia, corrected calcium based on albumin \\\u003C8.4 mg\u002FdL\n* Hypercalcemia, corrected calcium based on albumin \\>10.5 mg\u002FdL\n* Conditions that affect vitamin D metabolism such as: malabsorption, chronic kidney or liver disease, nephrocalcinosis, hyperparathyroidism\n* Current use of medications which are known to affect thyroid function or vitamin D metabolism such as thyroid hormone replacement, corticosteroids, anticonvulsants\n* Allergy to vitamin D or methimazole\n* Diagnosis of Hashitoxicosis or thyrotoxicosis (both TSH receptor antibody (TRAb) and thyroid-stimulating immunoglobulin (TSI) levels are negative)\n* Participants under the age of 9 years at the time of diagnosis\n* Pregnant participants\n* Active or uncontrolled infections, other significant medical conditions deemed by the investigator to interfere with study participation or pose undue risk to the participant.","9 Years","17 Years",{"count":146,"type":22},[86],"The goal of this randomized pilot feasibility clinical trial is to determine the feasibility of implementing a protocol for a larger trial to assess the effects of high-dose vitamin D supplementation in pediatric patients (9-17 years old) newly diagnosed with Graves' disease. The main questions it aims to answer are:\n\nWhat are the recruitment and adherence rates for a larger trial using this protocol? Is the data collection process complete and robust enough for a larger trial? What are the potential barriers to implementing a larger-scale trial? Researchers will compare vitamin D supplementation plus standard methimazole therapy to methimazole therapy alone (with participants permitted to take up to 1000 International Units of vitamin D2 daily) to explore potential effects on thyroid hormone and antibody levels.\n\nParticipants will:\n\nBe randomized to either the intervention or control group. Take study medications (vitamin D or placebo) as directed. Attend regular study visits for blood tests and clinical assessments. Complete medication logs.",[28,30,31],[392,334,191],"vitamin d","2026-01-23",{"date":395,"type":42},"2026-01-27",{"date":397,"type":42},"2025-08-01",{"date":399,"type":22},"2027-02-28",{"name":401,"class":266},"Northwell Health",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":409,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":420,"leadSponsor":421,"locationsCount":137},"100613035","early-phase-1-allogeneic-anti-cd19bcma-car-t-for-refractory-graves-disease-100613035","NCT07261345","Allogeneic Anti-CD19\u002FBCMA CAR-T for Refractory Graves' Disease","The Safety and Efficacy of Allogenic Anti-CD19\u002FBCMA CAR-T Cell Therapy for Refractory Graves' Disease","Inclusion Criteria (Participants must meet all of the following inclusion criteria to be eligible for this study):\n\n* Refractory Graves' disease, defined as meeting at least one of the following: a) Continuous treatment with antithyroid drugs (ATDs) for ≥3 years without achieving criteria for drug discontinuation. b) Meeting criteria for drug discontinuation but experiencing ≥2 relapses after withdrawal.\n* Positive serum TRAb.\n* Willing to voluntarily participate in this clinical study, able to sign informed consent, and compliant with follow-up requirements.\n\nExclusion Criteria (Participants will be excluded if any of the following conditions apply):\n\n* History of severe drug allergies or allergic constitution.\n* Presence or suspected presence of uncontrolled or active infections (including bacterial, fungal, viral, or other pathogens) requiring systemic or intravenous treatment.\n* Presence of central nervous system disorders (including epilepsy, psychosis, cerebrovascular accident, encephalitis, CNS vasculitis, etc).\n* Presence of clinically significant heart diseases (e.g., angina pectoris, myocardial infarction, heart failure, severe arrhythmias, etc).\n* Subjects with congenital immunoglobulin deficiency.\n* Subjects with malignancy (current or past), except for conditions deemed cured and with no risk of recurrence based on investigator assessment.\n* Positive viral serology, including any of the following: Hepatitis B surface antigen (HBsAg)-positive, or hepatitis B core antibody (HBcAb)-positive with HBV DNA above the upper limit; Hepatitis C virus (HCV) antibody-positive with detectable HCV RNA; Human immunodeficiency virus (HIV) antibody-positive; Positive syphilis test.\n* Severe psychiatric disorder or significant cognitive impairment that may affect compliance.\n* Hematologic dysfunction, including: a) White blood cell count \\\u003C 3.5 × 10⁹\u002FL; b) Neutrophil count \\\u003C 1.8 × 10⁹\u002FL; c) Hemoglobin \\\u003C 110 g\u002FL.\n* Hepatic dysfunction, defined as any of the following: Alanine aminotransferase (ALT) \\> 3 × ULN; Aspartate aminotransferase (AST) \\> 3 × ULN; Total bilirubin (TBIL) \\> 2.5 × ULN.\n* Renal dysfunction: creatinine clearance rate (CrCl) \\\u003C 60 mL\u002Fmin (Cockcroft-Gault formula).\n* Left ventricular ejection fraction (LVEF) \\\u003C 55%.\n* Coagulation abnormalities, defined as either: International normalized ratio (INR) \\> 1.5 × ULN; Prothrombin time (PT) \\> 1.5 × ULN.\n* Participation in another clinical trial within 3 months prior to enrollment.\n* Pregnant or breastfeeding women, or women planning to become pregnant.\n* Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.",{"count":410,"type":22},4,[250],"Graves' disease is an autoimmune thyroid disorder in which autoantibodies against the thyroid-stimulating hormone receptor (TRAb) lead to excessive thyroid hormone production and systemic complications, as well as thyroid eye disease and pretibial myxedema in some cases. Patients with refractory Graves' disease often fail to achieve durable remission despite prolonged antithyroid medication.\n\nThis study aims to evaluate the safety and efficacy of RD06-05, an allogeneic dual CD19\u002FBCMA CAR-T therapy, in participants with refractory Graves' disease, and will provide preliminary evidence on whether dual-targeting CAR-T therapy can induce sustained remission of refractory Graves' disease.",[30],[415,255,254],"CAR-T","2026-01-01",{"date":418,"type":42},"2026-01-05",{"date":44,"type":42},{"date":263,"type":22},{"name":265,"class":266},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":436,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":137},"100596521","thyroid-artery-goitre-embolization-trial-a-pilot-study-investigating-thyroid-artery-embolisation-as-a-treatment-for-large-thyroid-nodules-100596521","NCT07046546","Thyroid Artery Goitre Embolization Trial A Pilot Study Investigating Thyroid Artery Embolisation as a Treatment for Large Thyroid Nodules","Thyroid ARtery Goitre Embolization Trial: A Service Introduction and Safety Assessment","TArGET","Inclusion Criteria:\n\n* The participant may enter the study if ALL of the following apply:\n\n  * Adults over 18 years of age willing and able to give informed consent.\n  * Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease).\n  * Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre\n  * TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound.\n  * FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule.\n  * No enlarged \u002F suspicious neck lymphadenopathy on ultrasound.\n  * Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and \u002F or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options.\n  * Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.\n\nExclusion Criteria:\n\n* The participant may enter the study if ALL of the following apply:\n\n  * Adults over 18 years of age willing and able to give informed consent.\n  * Symptomatic or cosmetically distressing benign nodular thyroid disease with or without intrathoracic extension and with or without hyperthyroidism. Or auto-immune hyperthyroidism (Graves disease).\n  * Single nodular goitre causing local mass effect warranting treatment or multi-nodular goitre\n  * TIRADS score 1, 2 and 3 nodules (benign or mildly suspicious) as assessed by ultrasound.\n  * FNA confirmed benign disease (x2 FNA Thy2 (benign) result required for TR3 nodules, 1x FNA if nodule classified TR2 or less). FNA performed on most high grade nodule or if equal grade then largest nodule.\n  * No enlarged \u002F suspicious neck lymphadenopathy on ultrasound.\n  * Patient willing to undergo thyroid nodule embolization in preference to other viable treatment options after discussion with Consultant ENT surgeon and \u002F or Consultant Interventional Radiologist. TAE can also be performed as a bridge to surgery, Radiofrequency ablation or Radioactive iodine. Patients may also be unsuitable or unfit for other treatment options.\n  * Patient able to lay on the angiography table flat with one or two pillows, and can lay comfortably with 30 degrees or less of head elevation for a minimum of two hours.",{"count":352,"type":22},[326],"Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include radiofrequency ablation, radioactive iodine, and surgery. Not all patients are suitable however for these treatments, some lumps are too large, or the patients are not fit enough for surgery.\n\nThyroid artery embolization (TAE) is a new minimally invasive technique (smaller incisions \u002F cuts and shorter recovery time) performed under light sedation. It is used by other European Thyroid Centres, but it hasn't been used in the UK. Embolization means arteries supplying the thyroid gland are blocked by injecting small occlusive particles, like very fine grains of sand that can get stuck in small spaces, preventing blood from passing through. Blocking the thyroid arteries causes the gland to shrink. This provides symptom relief or controls an overactive gland.\n\nWe aim to undertake a TAE pilot study to explore the safety of TAE in a UK patient population. We are planning to recruit 10 eligible patients. We will also collect additional data (for example on pain, effectiveness, cost and health related quality of life) to inform a future larger trial comparing TAE to other treatment options.",[434,28,435],"Thyroid Nodule (Benign)","Goitre",[437,438],"Thyroid artery embolisation","Benign thyroid nodules","2025-12-23",{"date":441,"type":42},"2025-12-24",{"date":443,"type":42},"2025-09-29",{"date":102,"type":22},{"name":446,"class":447},"Royal Berkshire NHS Foundation Trust","OTHER_GOV",{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":185,"enrollmentInfo":455,"targetDuration":4,"studyType":23,"phases":457,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":137},"100539859","the-impact-of-person-centred-care-pcc-in-graves-disease-100539859","NCT06309316","The Impact of Person Centred Care (PCC) in Grave's Disease","The Impact of Person Centred Care (PCC) on Mental Outcome and Work Ability in Graves' Disease - the GRAves CarE (GRACE) PCC Project","Inclusion Criteria:\n\n* Age 18-65 years\n* First time Graves' diseases with elevated FT4 and\u002For FT3 and positive TSH receptor antibody (TRAb)\n\nExclusion Criteria:\n\n* Patients that cannot attend to the protocol\n* Patients with moderate-severe\u002F severe Graves' eye disease",{"count":456,"type":22},220,[326],"Mental fatigue (MF) is prevalent after Graves' disease (GD), which is the most common form of hyperthyroidism. We have reported that 38% of patients, compared to 11% of control subjects, suffer from MF more than 1 year after successfully reversing of their hyperthyroidism and that MF is an entity of its own, separated from MF combined with anxiety or depression. The brain pathophysiology is unknown and there is no medical treatment, which requires patients to simply adapt to the situation. In the new national guideline for hyperthyroidism (Jan 2023), rehabilitation is recommended, but currently rarely offered to these patients. The problem is significant for patients, as illustrated by frequent media appeals. In this project, we hypothesise that person-centred care (PCC), which promotes positive coping strategies and increases self-efficacy by engaging patients as partners in their own care, improves MF, reduces sick leave, and lowers the recurrence rate of GD. In two work packages (WP), we will:\n\nWP1 Evaluate the effect of PCC eHealth intervention (telephone and digital platform) as an add-on to usual care vs usual care alone in a randomized controlled trial (RCT) of 220 patients on self-efficacy, days of sick-leave (composite score as primary outcome), MF, recurrence rate of disease, coping strategies, perceived stress, quality of life (QoL) and personality.\n\nWP2 Investigate the cost-effectiveness of the intervention\n\nPatients with GD have impaired long-term QoL. PCC could improve long-term outcomes of this autoimmune disease and may apply to other patient groups. This is in line with the societal aim to reduce mental illness.",[28],[461,462,463,464,465],"Person Centred Care","Mental fatigue","cost-effectiveness","self-efficacy","eHealth","2025-11-17",{"date":312,"type":42},{"date":469,"type":42},"2024-03-25",{"date":471,"type":22},"2030-01-30",{"name":473,"class":447},"Vastra Gotaland Region",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":488,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":137},"100526398","course-for-brain-fatigue-after-graves-disease-controlled-study-100526398","NCT06134219","Course for Brain Fatigue After Graves' Disease Controlled Study","A Mental Fatigue Course to Graves' Disease Patients With Mental Fatigue -a Randomized Controlled Study","MF-Course","Inclusion Criteria:\n\n* 18-72 years old\n* 15-72 months since first Graves' diagnosis\n* high free thyroxin and thyroid antibodies (TRAb) at diagnosis\n* euthyroid the last 6 months normal thyroid hormone levels at inclusion\n* symptoms on MF in connection to Graves diagnosis\n* MF-scale ≥10.5 points\n\nExclusion criteria:\n\n* other diseases or situations that may be associated with mental fatigue (such as other active inflammatory disease, neurological disease)\n* pregnancy\n* lactation\n* assessment that the patient cannot follow the study protocol.","72 Years",{"count":484,"type":22},96,[326],"BACKGROUND. Mental fatigue (MF) is common in the most common form of hyperthyroidism, Graves' disease (GD). Clinically, MF is the primary mental symptom in patients with GD and is characterized by difficulties maintaining attention, exhaustion during cognitively demanding tasks, memory difficulties, irritability, and emotional lability. It may be the main contributing factor to the continued low quality of life in many patients with GD. MF can be measured with an MF score (MFS). The pathophysiology is unknown. There is no medical treatment, which requires patients to adapt to the situation.\n\nAIM. In this project, the investigators want to test the hypothesis that mental fatigue improves - with secondary benefits on mental capacity, quality of life (QoL), and function - in patients with persistent mental fatigue in GD, through an MF course as an addition to standard care, compared to patients who receive only standard care. The investigators also test the hypothesis that the MF course is a cost-effective intervention.\n\nMETHOD. In a randomized controlled study, the investigators evaluate the effect of the MF course compared to standard care only in 96 patients with persistent MF in GD. Markers of mental health, QoL, and activity capacity are evaluated at baseline, 3, 6, and 12 months after intervention\u002Finclusion. The primary outcome measure is MFS at 3 months.\n\nCLINICAL SIGNIFICANCE. Patients report feeling neglected by healthcare for decades, and healthcare professionals are frustrated by the lack of guidance. Patient organizations highlight the need for research; they want mental symptoms to be characterized as a consequence of thyroid disease, they demand biomarkers, specific treatments, and personalized care. Our research group is working to address the cause of MF in GD and also to alleviate the symptoms. The MF course may prove to be an important tool that can be quickly implemented in clinical practice, especially in primary care. Our involvement in regional\u002Fnational working groups will facilitate implementation in other units.\n\nIn this project, the investigators want to test the hypothesis that mental fatigue improves - with secondary benefits on mental capacity, quality of life (QoL), and function - in patients with persistent mental fatigue at GD, through an MF course as an addition to regular healthcare, compared to patients receiving only regular healthcare.",[28],[462],{"date":312,"type":42},{"date":491,"type":42},"2023-10-10",{"date":493,"type":22},"2027-05-10",{"name":473,"class":447},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":502,"maxAge":185,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":137},"100325481","personalized-treatment-in-thyroid-disorders-100325481","NCT03517579","Personalized Treatment in Thyroid Disorders","Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease","Inclusion Criteria:\n\n* Group I\n\n  * Patients with Graves' disease confirmed by laboratory testing.\n  * Patients able to understand English and able to follow instructions. Group II\n  * Patients with intermediate and high risk differentiated thyroid cancer requiring radioiodine remnant ablation or moderately high dose I-131 for treatment of residual cervical disease.\n  * Persons able to understand simple English and able to follow instructions.\n\nExclusion Criteria:\n\n* Patients with diseases involving cervical spine, such as spondylosis and severe degenerative joint disease.\n* Pregnant Women, elderly and persons unable to understand simple instructions","21 Years",{"count":352,"type":22},[326],"The Collar Therapy Indicator (CoTI) (A device that is placed in collar around the neck resembling a turtle neck sweater collar with a wire and recording box) has been shown in a single small previously published experience to provide data regarding radioiodine exposure that correlates with conventional methods of measuring I-123 and I-131 uptakes after diagnostic dose administration and\u002For therapy for thyroid disorders. We hypothesize that the device's continuous measurement capability will permit more accurate estimates of radiation exposure to thyroid tissue than conventionally employed methods assessing fractional uptake at one or a few time points. It may also provide information about the extent of variability in the absorbed radiation dose among patients with thyroid cancer and hyperthyroidism. By providing more complete information about individual patient's exposures, it will facilitate more accurate estimation of the administered I-131 dose requirements for control of hyperthyroidism and thyroid remnant ablation while reducing the need for repeated visits to the clinic for dosimetry measurements. The aims of our project include the following: (1)To compare quantitative imaging-derived thyroid time activity curve to that obtained using the CoTI and to determine the extent to which there is variability in radiation dose predicted using conventional methods to that predicted from measurement of the full Time-Activity Curve (TAC).(2) Evaluate the uptake and clearance kinetics across the 5 patients in each category as proof of principle for a potential larger trial to investigate use of this device in optimizing the administered doses of radioactive iodine to achieve therapeutic goals while minimizing risks of comorbidities, such a post-radioiodine hypothyroidism in patients with Graves' disease.(3)Evaluate patient experience, convenience, and discomfort in using the CoTI device with a survey instrument.",[329,28],"2025-10-13",{"date":509,"type":42},"2025-10-15",{"date":511,"type":42},"2018-12-11",{"date":513,"type":22},"2027-12-15",{"name":515,"class":266},"Johns Hopkins University",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":274,"sex":523,"minAge":18,"maxAge":482,"enrollmentInfo":524,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":526,"conditions":527,"keywords":531,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":137},"100491380","exploring-immunological-markers-associated-with-mental-fatigue-in-graves-disease-100491380","NCT05678374","Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease","Exploring Immunological Markers in Blood and Cerebrospinal Fluid Associated With Mental Fatigue in Euthyroidism After Graves' Disease- a Cross Sectional Study","Inclusion Criteria\n\n* If patient: Graves' disease with positive TSH-receptor antibodies and thyroid hormones above the upper reference limit at diagnosis\n* Diagnosis15 to 60 months ago. If recidive both episodes must have occurred within 15 months to 60 months.\n* Thyroid hormones within normal range without anti thyroid drugs\n* If control: No thyroid disease\n* Patient and control without mental fatigue: Mental Fatigue Score ≤8 (cut off 10.5)\n* Patient with mental fatigue: Mental Fatigue Score \\>13 and debut of symptoms of mental fatigue in parallel with debut of Graves' disease, without other obvious cause\n\nExclusion Criteria\n\n* Person unable to follow protocol\n* Multiple sclerosis, myalgic encephalomyelitis\u002Fchronic fatigue syndrome, any other neurological disease\n* Traumatic brain injury with unconsciousness\n* Other disease strongly associated with fatigue\n* Pregnancy and breast-feeding\n* On-going or recent systemic treatment with steroids\n* Radioiodine therapy within the last 18 months","FEMALE",{"count":525,"type":22},180,"Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored hyperthyroidism in Graves' disease is an autoimmune complication. The aim of this study is to explore immunological markers possibly associated with mental fatigue in Graves' disease, which the investigators plan to validate in another study (ImmunoGraves wp 2).\n\nUsing a cross-sectional study design, mental fatigue is scored using a questionnaire to find 60 patients with and 60 without mental fatigue 15-60 months after diagnosis of Graves disease. The patients and 60 thyroid healthy controls without mental fatigue are assessed for thyroid hormones, quality of life, anxiety and depression, self-evaluated stress, coping strategies, eye symptoms and background variables. SciLifeLab in Stockholm, the national facility for autoimmune profiling, has pre-set large arrays including 42000 human proteins. Serum and cerebrospinal fluid will be separately pooled and analysed for a subgroup of patients with or without mental fatigue and for a subgroup of the control group. Proteins that preferably bind to antibodies in sera and\u002For cerebrospinal fluid from Graves' patients with mental fatigue in comparison to non-mental fatigue patients, will be screened against the Human Protein Atlas and the Allen brain map to identify those proteins that are expressed in the brain. Antibodies at higher concentration in the mental fatigue pools compared to the group without mental fatigue will be selected for further analyses on an individual level in the whole cohort together with antibodies targeting g-protein coupled receptors, thyroid autoantibodies, cytokines and biomarkers indicating organic and structural nerve damage.",[28,278,528,529,530],"Mental Fatigue","Autoimmune Diseases","Thyroid Diseases",[532,533],"Biomarkers","Cerebrospinal fluid in Graves' disease","2025-09-23",{"date":443,"type":42},{"date":537,"type":42},"2019-10-01",{"date":539,"type":22},"2028-12-20",{"name":473,"class":447},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":548,"targetDuration":4,"studyType":23,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":563},"100582518","prospective-evaluation-of-optithydose-100582518","NCT06864351","Prospective Evaluation of OptiThyDose","Prospective Evaluation of OptiThyDose, a Mathematical Model for Calculating Appropriate Dose Ranges in Children With Thyroid Diseases","Inclusion Criteria:\n\nCongenital hypothyroidism (CH)\n\n* Newborns with pathological neonatal screening and confirmation of an increased Thyrotropin (TSH) level in an independent venous blood sample\n\nGraves' disease (GD)\n\n* Children until 18 years with new diagnosis of GD, recurrence of GD, or insufficiently controlled GD under CMZ\u002FMMZ during follow-up according to:\n\n  * Pathological lab values (suppressed TSH, increased thyroid hormone levels, positive Anti-TSH-receptor antibodies)\n  * Typical clinical picture, if present (goitre, tachycardia, palpitations, weight loss, hyperphagia, altered mood)\n\nCH and GD\n\n* The study participant must be accessible for scheduled visits, treatment and follow-up.\n* Signed Informed Consent form (ICF) obtained prior to any study related procedure. Written IC for study participation must be signed and dated by the patient and\u002For his\u002Fher legal representative(s) in accordance with national legal requirements\n\nExclusion Criteria:\n\nCH and GD\n\n* Exclusion of newborns from mothers with GD\n* Exclusion of patients in case of a life-threatening event\n\nGD\n\n* Exclusion of children with known other aetiologies of hyperthyroidism than GD without elevated Anti-TSH-receptor antibodies e.g.:\n\n  * known toxic thyroid nodules proven by ultrasound\u002Fscintigraphy\n  * known amiodarone induced hyperthyroidism\n  * known McCune Albright syndrome (based on clinical, laboratory, and genetic diagnosis) associated hyperthyroidism\n  * known genetically proven hyperthyroidism caused by activating mutations of the TSH receptor gene",{"count":549,"type":22},150,[326],"The aim of this multicentric, randomised, two-arms and single-blinded clinical trial is to prospectively evaluate OptiThyDose for Congenital hypothyroidism (CH) and Graves' disease (GD).",[530,553,28],"Congenital Hypothyroidism","2025-09-01",{"date":556,"type":42},"2025-09-03",{"date":558,"type":42},"2025-08-28",{"date":560,"type":22},"2029-02",{"name":562,"class":266},"University Children's Hospital Basel",2,{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":185,"enrollmentInfo":571,"targetDuration":4,"studyType":23,"phases":572,"briefSummary":573,"conditions":574,"keywords":575,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":137},"100602909","early-phase-1-allogeneic-anti-cd19-car-t-for-refractory-graves-disease-100602909","NCT07129642","Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease","The Efficacy and Safety of Allogenic Anti-CD19 CAR-T Cell Therapy for Refractory Graves' Disease","Inclusion Criteria:\n\n* Subjects with refractory Graves disease, which is defined as meeting any one of the following criteria: a. Failure to discontinue medication after continuous standard antithyroid therapy for ≥ 3 years; b. Hyperthyroid state requiring medication after receiving ≥ 2 times of radioiodine therapy (with the last dose of radioiodine administered at least 6 months prior); c. Relapse ≥ 2 times after cessation of medication upon meeting the criteria for treatment discontinuation.\n* Serum TRAb ≥ 3 times greater than normal range (≥ 5 IU\u002FL)\n* Positive expression of CD19 on peripheral blood B cells determined by flow cytometry.\n* Participation in this clinical study is willing to sign an informed consent with good compliance with treatment and follow-up.\n\n(Criteria for treatment discontinuation is define as receiving continuous anti-thyroid drug therapy for ≥18 months, and maintaining euthyroid status for ≥6 months, plus negative TRAb and TSI. Relapse is defined as recurrence of hyperthyroidism and positive TRAb\u002FTSI after meeting the criteria for treatment discontinuation and stopping medication.)\n\nExclusion Criteria:\n\n* History of severe drug allergies or allergic constitution;\n* Presence or suspicion of uncontrolled infections requiring intravenous treatment (fungal, bacterial, viral or other);\n* Presence of central nervous system disorders (including epilepsy, psychosis, cerebrovascular accident, encephalitis, CNS vasculitis, etc);\n* Presence of clinically significant heart diseases (e.g., angina pectoris, myocardial infarction, heart failure, severe arrhythmias, etc);\n* Subjects with congenital immunoglobulin deficiency;\n* Patients with malignant tumors;\n* Subjects who are: 1. HBsAg or HBcAb positive with detectable peripheral blood HBV DNA; 2. HCV antibody positive with detectable HCV RNA; 3. Positive HIV antibody; 4. Syphilis test positive;\n* Subjects with psychiatric disorders or severe cognitive dysfunction;\n* Hematopoietic function: a. White blood cell count \\\u003C 3.5×10\\^9\u002FL b. Neutrophil count \\\u003C 1.5 x 10\\^9\u002FL; c. Hemoglobin \\\u003C 110g\u002FL.\n* Liver function: ALT\\> 3×ULN, AST \\> 3×ULN, TBIL \\> 2.5×ULN.\n* Renal function: creatinine clearance rate (CrCl) \\\u003C 60 ml\u002Fminute (calculated based on Cockcroft\u002FFault formula).\n* Cardiac function: LVEF \\\u003C 55%\n* Coagulation function: International standardized ratio (INR) ≥ 1.5×ULN, prothrombin time(PT) \\>1.5 × ULN.\n* Participation in other clinical trials within 3 months prior to enrollment;\n* Pregnancy or planning pregnancy;\n* Other conditions considered by investigators as unsuitable for participation.",{"count":74,"type":22},[250],"Graves' disease is an autoimmune disease. The TSH receptor antibody(TRab) produced by B cells drives the production of thyroid hormone, which causes systemic disorders and thyroid eye disease. The purpose of this study is to investigate the efficacy and safety of allogeneic anti-CD19 CAR-T for refractory Graves' disease.\n\nThe participants with refractory Graves' disease will receive a single dose of allogeneic anti-CD19 CAR-T and be regularly seen for the change of serum TRab, FT3, FT4 and clinical presentations, as well as any adverse events.",[28],[415,576,255],"refractory Graves disease","2025-08-16",{"date":579,"type":42},"2025-08-19",{"date":581,"type":22},"2025-08-10",{"date":583,"type":22},"2027-03-31",{"name":265,"class":266},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":593,"targetDuration":595,"studyType":117,"phases":4,"briefSummary":596,"conditions":597,"keywords":598,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":137},"100597516","prevalence-and-predictors-of-incidental-thyroid-carcinoma-in-patients-with-graves-disease-undergoing-thyroidectomy-100597516","NCT07059507","Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy.","Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy: A Prospective Study.","GD","Inclusion Criteria:\n\n* Age 18 years or older.\n* Confirmed diagnosis of Graves' disease based on clinical features (e.g., diffuse goiter, ophthalmopathy if present) and biochemical evidence (suppressed TSH, elevated free T4 and\u002For T3) and\u002For positive TSH receptor antibody (TRAb) test.\n* Indication for total thyroidectomy for Graves' disease, based on established guidelines:\n\nRelapse or persistence of hyperthyroidism after a course of antithyroid drugs (ATDs).\n\nIntolerance or adverse reaction to ATDs. Patient preference for surgery over radioactive iodine (RAI) or long-term ATDs. Presence of a large goiter causing compressive symptoms. Coexisting suspicious thyroid nodule(s) on preoperative evaluation. Moderate to severe active Graves' ophthalmopathy where RAI is relatively contraindicated.\n\n* Patient is scheduled for total thyroidectomy (near-total or subtotal thyroidectomy patients will be excluded).\n* Ability and willingness to provide written informed consent.\n* Ability to understand study procedures and requirements.\n\nExclusion Criteria:\n\n* Age less than 18 years.\n* Previous thyroid surgery.\n* Previous neck irradiation.\n* Preoperative diagnosis of thyroid malignancy confirmed by fine-needle aspiration (FNA) cytology (Bethesda V or VI) , the focus is on incidental carcinoma.\n* Inability to provide informed consent (e.g., due to cognitive impairment).\n* Patients undergoing thyroidectomy primarily for reasons other than Graves' disease (e.g., primary indication is large non-toxic MNG).\n* Patients undergoing less than total thyroidectomy (e.g., lobectomy, subtotal thyroidectomy).",{"count":594,"type":22},280,"1 Month","The prevalence of incidental thyroid cancer (ITC) in Graves' Disease (GD) patients undergoing thyroidectomy appears higher than historically believed, potentially exceeding 10% in large contemporary series, although significant variability exists. The presence of nodules is a strong predictor, while the roles of age, sex, and BMI require clarification. Most ITCs are papillary thyroid microcarcinoma(PTMCs) with generally favorable prognoses, but concerns about aggressiveness persist.\n\nThe purpose of the present study is to accurately evaluate the prevalence of incidental thyroid carcinoma (ITC), including microcarcinomas, in a prospectively enrolled cohort of patients undergoing total thyroidectomy for Graves' disease, utilizing standardized pathological examination protocols and secondary outcomes including predictors and histopathological characteristics.",[329,28],[599],"Incidental thyroid cancer","2025-07-14",{"date":602,"type":42},"2025-07-17",{"date":604,"type":42},"2025-07-15",{"date":606,"type":22},"2026-08-15",{"name":608,"class":266},"Minia University",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":616,"targetDuration":618,"studyType":117,"phases":4,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":137},"100596042","a-clinical-follow-up-study-on-drug-therapy-for-graves-disease-patients-in-china-100596042","NCT07040306","A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China","A Prospective Clinical Follow-up Study of Drug Treatment in Patients With Graves' Disease","Inclusion Criteria:\n\n1. Age ≥18 years old.\n2. Newly diagnosed GD and GD relapses.\n\nExclusion Criteria:\n\n1. Patients with active infiltrative exophthalmos in GD were excluded.\n2. Patients with other autoimmune diseases affecting thyroid function were excluded.\n3. Excluding patients with combined malignancies and other serious diseases.",{"count":617,"type":22},1000,"30 Years","This study was a prospective follow-up study of newly diagnosed and relapsed Graves' disease patients in the Endocrinology Clinic of the First Affiliated Hospital of China Medical University. The following aspects will be studied: 1. Through the prospective follow-up study of GD patients, we will get the relapse rate and remission rate of GD patients treated with drugs, explore the risk factors of GD patients relapsing after drug treatment, and make GD relapse risk prediction software; 2. To compare the effects of high dose and low dose methimazole on the remission rate, liver side effects, leukopenia and other adverse drug reactions, and to summarize the incidence and risk factors of liver side effects, leukopenia and other adverse drug reactions caused by drug treatment; 3. To investigate the sensitivity and specificity of TRAb in the diagnosis of GD in China and its role in predicting recurrence; 4. After taking ATD, the serum alkaline phosphatase of GD patients will increase first and then decrease. This study will focus on analyzing the dynamic changes of this index before and after methimazole treatment, and analyze the relationship between it and thyroid function index.",[621],"Graves´ Disease","2025-07-03",{"date":624,"type":42},"2025-07-09",{"date":626,"type":42},"2012-11-14",{"date":628,"type":22},"2030-12-01",{"name":630,"class":266},"First Hospital of China Medical University"]